XALATAN

This brand name is authorized in United States. It is also authorized in Australia, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Germany, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Malta, Mexico, Netherlands, Nigeria, Poland, Romania, Singapore, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug XALATAN contains one active pharmaceutical ingredient (API):

1	Latanoprost UNII 6Z5B6HVF6O - LATANOPROST
	The active substance latanoprost, a prostaglandin F2α analogue, is a selective prostanoid FP receptor agonist which reduces the intraocular pressure (IOP) by increasing the outflow of aqueous humour. Reduction of the IOP in man starts about three to four hours after administration and maximum effect is reached after eight to twelve hours.
	Read more about Latanoprost

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
XALATAN Ophthalmic solution	MPI, US: SPL/PLR	FDA, National Drug Code (US)
XALATAN Eye drops, solution	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
S01EE01	Latanoprost	S Sensory organs → S01 Ophthalmologicals → S01E Antiglaucoma preparations and miotics → S01EE Prostaglandin analogues
Discover more medicines within S01EE01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	5552F, 8243W
BR	Câmara de Regulação do Mercado de Medicamentos	552820060069217
CA	Health Products and Food Branch	02231493
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	00721047, 00721136, 00721219, 04385037, 04385043, 04385089, 06148169, 09537351, 09537368, 10073520, 10073537, 10073543, 10090375, 10090381, 10090398, 10218668, 10268212, 10268229, 10268235, 10710151, 10710168, 10817593, 10817618, 10817624, 11874392, 11874400, 11874417, 14018570, 15863586, 16527620
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	29697-03-11
EE	Ravimiamet	1041196, 1078095
ES	Centro de información online de medicamentos de la AEMPS	61756, BE183967
FI	Lääkealan turvallisuus- ja kehittämiskeskus	124735, 124743
FR	Base de données publique des médicaments	60047271
GB	Medicines & Healthcare Products Regulatory Agency	13819, 139791, 147628, 164478
HK	Department of Health Drug Office	42158
HR	Agencija za lijekove i medicinske proizvode	HR-H-173193826
IE	Health Products Regulatory Authority	53420, 53473
IL	מִשְׂרַד הַבְּרִיאוּת	3815
IT	Agenzia del Farmaco	033219015, 044895011, 046107013
JP	医薬品医療機器総合機構	1319739Q1037
LT	Valstybinė vaistų kontrolės tarnyba	1003206, 1082998
MT	Medicines Authority	MA1396/01101, PI770/15001A
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	043M98
NG	Registered Drug Product Database	04-4198
NL	Z-Index G-Standaard	14145332
NL	Z-Index G-Standaard, PRK	48216
PL	Rejestru Produktów Leczniczych	100085967, 100373620
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W67251001, W67251002
SG	Health Sciences Authority	09549P
TN	Direction de la Pharmacie et du Médicament	10803081, 4143011
TR	İlaç ve Tıbbi Cihaz Kurumu	8699759610015
US	FDA, National Drug Code	0013-8303
ZA	Health Products Regulatory Authority	31/15.4/0614